Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group

References

• Cohen AD, Wu JJ, Puig L, et al. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. Br J Dermatol. 2017;177(6):1495–1502.
   PubMed Web of Science ®Google Scholar
• Simoens S. Biosimilar medicines and cost-effectiveness. 2011;ClinicoEconomics and outcomes research: CEOR. 3:29–36.
   PubMedGoogle Scholar
• Cakan M, Ayaz NA, Karadag SG, et al. The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis. North Clin Istanb. 2020;7(2):118–123.
   PubMed Web of Science ®Google Scholar
• Radtke MA, Augustin M. Biosimilars in psoriasis: what can we expect? J Dtsch Dermatol Ges. 2014;12(4):306–312.
   PubMed Web of Science ®Google Scholar
• Zhao S, Chadwick L, Mysler E, et al. Review of biosimilar trials and data on adalimumab in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20(10):57.
   PubMed Web of Science ®Google Scholar
• Norman P. Humira(®): recent developments. Pharm Pat Anal. 2017;6(3):89–90.
   PubMed Web of Science ®Google Scholar
• Coghlan J, He H, Schwendeman AS. Overview of humira® biosimilars: current european landscape and future implications. J Pharm Sci. 2021;110(4):1572–1582.
   PubMed Web of Science ®Google Scholar
• Reynolds KA, Pithadia DJ, Lee EB, et al. Safety and effectiveness of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis. Am J Clin Dermatol. 2020;21(4):483–491.
   PubMed Web of Science ®Google Scholar
• Bellinvia S, Cummings JRF, Ardern-Jones MR, et al. Adalimumab biosimilars in Europe: an overview of the clinical evidence. BioDrugs. 2019;33(3):241–253.
   PubMed Web of Science ®Google Scholar
• Maccora I, Lombardi N, Crescioli G, et al. OBSIDIAn - real world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis. Rheumatology (Oxford). 2021. 10.1093/rheumatology/keab572.
   Google Scholar
• Sözeri B, Kardeş E, Salı E, et al. Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis. Clin Exp Rheumatol. 2021;39(4):907–912.
   PubMed Web of Science ®Google Scholar
• Sozeri B, Emine Sonmez H, Demir F, et al. Time to collaborate: objectives, design, and methodology of PeRA-research group. North Clin Istanb. 2021;8(2):200–202.
   PubMed Web of Science ®Google Scholar
• Türkiye İlaç ve Tıbbi Cihaz Kurumu. İlaç Güvenlik İzlem Formuyla Kullanılan İlaçlar Listesi 2021. [cited 2021 Sep 10]. Available from: https://www.titck.gov.tr/dinamikmodul/110.
   Google Scholar
• Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
   PubMed Web of Science ®Google Scholar
• Martini A, Ravelli A, Avcin T, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46(2):190–197.
   PubMed Web of Science ®Google Scholar
• Reininga JK, Los LI, Wulffraat NM, et al. The evaluation of uveitis in juvenile idiopathic arthritis (JIA) patients: are current ophthalmologic screening guidelines adequate? Clin Exp Rheumatol. 2008;26(2):367–372.
   PubMed Web of Science ®Google Scholar
• Consolaro A, Bracciolini G, Ruperto N, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheumatism. 2012;64(7):2366–2374.
   PubMed Web of Science ®Google Scholar
• Consolaro A, Giancane G, Schiappapietra B, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2016;14(1):23.
   PubMed Web of Science ®Google Scholar
• Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheumatism. 2009;61(5):658–666.
   PubMed Web of Science ®Google Scholar
• Weiss PF, Colbert RA, Xiao R, et al. Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis Care Res (Hoboken). 2014;66(12):1775–1782.
   PubMed Web of Science ®Google Scholar
• Information for Healthcare Professionals. Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (Adalimumab), and Remicade (infliximab). [cited 2021 Feb 25]. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-tumor-necrosis-factor-tnf-blockers-marketed-remicade-enbrel-humira-cimzia-and-simponi
   Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005 Rev1. 2014 . [cited 2021 Nov 12]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf.
   Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–1620.
   PubMed Web of Science ®Google Scholar
• Aragon Cuevas O, Hedrich CM. Biosimilars in pediatric rheumatology and their introduction into routine care. Clin Immunol. 2020;216:108447.
   PubMed Web of Science ®Google Scholar
• Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with Adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76(10):1679–1687.
   PubMed Web of Science ®Google Scholar
• Bakalos G, Zintzaras E. Drug discontinuation in studies including a switch from an originator to a biosimilar monoclonal antibody: a systematic literature review. Clin Ther. 2019;41(1):155–73.e13.
   PubMed Web of Science ®Google Scholar
• Kapoor S, Kaushik VV, Jain R, et al. Real-life tolerability and effectiveness of adalimumab biosimilar in ankylosing spondylitis: the adalimumab biosimilar patient registry data. ACR Open Rheumatol. 2019;1(8):480–484.
   PubMedGoogle Scholar
• Kapoor S, Kaushik VV, Jain R, et al. Real-Life tolerability and effectiveness of adalimumab biosimilar in rheumatoid arthritis: ASPIRE registry data. Rheumatol Ther. 2019;6(3):451–459.
   PubMed Web of Science ®Google Scholar
• Cabrera N, Lega JC, Kassai B, et al. Safety of biological agents in paediatric rheumatic diseases: a real-life multicenter retrospective study using the JIRcohorte database. Joint Bone Spine. 2019;86(3):343–350.
   PubMed Web of Science ®Google Scholar
• Chopra A, Mitra D, Agarwal R, et al. Real-life efficacy and safety of biosimilar adalimumab (ZRC-3197) in patients with plaque psoriasis: a tertiary care center experience. Indian Dermatol Online J. 2020;11(2):182–186.
   PubMedGoogle Scholar
• Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76(6):1093–1102.
   PubMed Web of Science ®Google Scholar
• Thiele F, Klein A, Hospach A, et al. Efficacy and safety of etanercept biosimilars compared with the originator for treatment of juvenile arthritis: a prospective observational study. ACR Open Rheumatol. 2021. 10.1002/acr2.11325.
   PubMedGoogle Scholar
• Maleki A, Manhapra A, Asgari S, et al. Tocilizumab employment in the treatment of resistant juvenile idiopathic arthritis associated Uveitis. Ocul Immunol Inflamm. 2021;29(1):14–20.
   PubMed Web of Science ®Google Scholar
• Marelli L, Romano M, Pontikaki I, et al. Long Term experience in patients with JIA-Associated Uveitis in a large referral center. Front Pediatr. 2021;9:682327.
   PubMed Web of Science ®Google Scholar
• Quartier P. Juvenile idiopathic arthritis-associated chronic uveitis: recent therapeutic approaches. J Clin Med. 2021;10(13):13.
   Web of Science ®Google Scholar
• Maccora I, Dell’anna MP, Vannacci A, et al. Safety evaluations of adalimumab for childhood chronic rheumatic diseases. Expert Opin Drug Saf. 2020;19(6):661–671.
   PubMed Web of Science ®Google Scholar
• Odinet JS, Day CE, Cruz JL, et al. The biosimilar nocebo effect? A systematic review of double-blinded versus open-label studies. J Manag Care Spec Pharm. 2018;24(10):952–959.
   PubMed Web of Science ®Google Scholar
• Colloca L, Panaccione R, Murphy TK. The clinical implications of nocebo effects for biosimilar therapy. Front Pharmacol. 2019;10:1372.
   PubMed Web of Science ®Google Scholar
• Müskens WD, Rongen-van Dartel SAA, Adang EMM, et al. Biosimilars in the management of chronic inflammatory diseases: the dutch experience. Mediterranean journal of rheumatology. 2019;30(Suppl 1):76–81
   PubMedGoogle Scholar